Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin +/- Irinotecan in Ewing Sarcoma
NCT05042934Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2021
- Primary completion
- Aug 2022
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of lurbinectedin in Ewing sarcoma, sponsored by University of Texas MD Anderson Cancer Center. Planned start Sep 2021; status: withdrawn.
02
Drugs
lurbinectedin
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT05042934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05042934.